RBC Capital analyst Luca Issi initiated coverage of Argenx (ARGX) with an Outperform rating and $850 price target The firm’s doctor checks suggest Vyvgart uptake is likely to accelerate from here given continued execution in approved indications and more convenient dosing. Argenx is a rare biotech company with $2B in sales that may quadruple by the end of the decade, result in $10B in cumulative operating cash flows, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx treatment of idiopathic inflammatory myopathy granted orphan designation
- Argenx’s Long-term Safety Study on Efgartigimod for Pediatric Myasthenia Gravis: Key Insights for Investors
- Argenx’s Promising CIDP Treatment: A Closer Look at the Efgartigimod PH20 SC Study
- Argenx’s Efgartigimod Study: A Potential Breakthrough for Lupus Nephritis
- Argenx price target raised to EUR 700 from EUR 680 at Barclays